Enough is Enough! Concerned Shareholders Confirm Resounding Support for Much Needed Change to Hemostemix Board of Directors and Executive Management

CALGARY, ALBERTA--(Marketwired - Sept. 6, 2016) -

• Concerned Shareholders urge ALL shareholders to VOTE the BLUE Form to VOTE for positive CHANGE.
• Concerned Shareholders reiterate worst fears confirmed by Q2 Results and misleading incorrect information asserted by entrenched Management of Hemostemix.

Barry Ullet, Bernie Troitsky, Donn Lovett, Glynn Hendry, Jed M. Wood, Jim Brown, Joseph P. Stewart, Dr. Owen Schwartz, Dr. Pierre Liemgruber, Robert Achtymichuk, Robert Sweep, Rodney Cavanagh, Rodney Risling and Todd Reinhart, shareholders (collectively, the "Concerned Shareholders") of Hemostemix Inc. ("Hemostemix" or the "Company"), wish to once again thank shareholders for the resounding support they have received to date and remind those who have not voted the BLUE form as of yet, to vote today by 12 p.m. (Calgary Time).

Shareholders are also urged to read the Concerned Shareholders' September 3^rd news release which addresses the troubling Q2 results, and corrects purposeful misleading information from management of the Company ("Management"). Additionally, further updates on the Concerned Shareholders' progress and transition planning is also provided. The Concerned Shareholders' September 3^rd news release can be found at: http://www.marketwired.com/press-release/concerned-shareholders-thank-hemostemix-inc-shareholders-resounding-support-much-needed-2155296.htm.

Certain Highlights of the Concerned Shareholders' September 3, 2016 News Release

Troubling details of the Company under current Management's leadership include but not limited to the following,

	x	the Company appears to be effectively insolvent based on the Q2 Results;
	x	cash position was a mere $127,267 combined with a current rate of spending of $218,624.50 per month and no active clinical trials;
	x	the outrageous details of the Insider Loan Proposal to a still undisclosed supposedly "arm's length party"allowing this unknown "arm's length party" to seize all of the Company's assets for a mere $1 million if the Company defaults, and become the Company's largest shareholder with 12,500,000 shares without approval from shareholders being sought by Management; and
	x	the Company no longer has a service provider to operate a clinical trial.

Supporting the Concerned Shareholders' will bring positive change including,

	•	a new board of directors consisting of a slate of highly qualified executives, investors in public and private companies, and entrepreneurs with track records of placing shareholders' interests first and proven ability to creating value;
	•	a sound strategic plan with timelines, as described in the Concerned Shareholders proxy circular, to enhance shareholder value;
	•	the support of highly qualified clinical scientists and medical professionals, including a Professor of Medicine and Biochemistry & Molecular Biology who have all agreed to help rebuild a strong and capable team to assist in the transition plan relating to the clinical science and biotechnology expertise required for the Company going forward; and
	•	advanced plans to raise a minimum of $4,000,000 to stabilize the Company and fund the continuation of the collection of interim data and the Phase 2 Trial on reasonable commercial terms and with a view to involving current shareholders generally if and as permitted, whether via rights offering or otherwise. Drive Capital has agreed to underwrite or top-up this financing as necessary.

Shareholders are encouraged to read the Concerned Shareholders' September 3^rd news release for more detailed information on these and other points. (See: http://www.marketwired.com/press-release/concerned-shareholders-thank-hemostemix-inc-shareholders-resounding-support-much-needed-2155296.htm

Shareholder Support For Change

Over 41% of the issued and outstanding shares of Hemostemix have voted with the BLUE voting forms thus far:

• Over 140 identified shareholders have voiced their support based on the Concerned Shareholders direct contact with them as part of the current proxy contest.
• Beyond 10 management shareholders identified in the concerned Shareholders outreach, the only active resistance the Concerned Shareholders have encountered is from:
  • the consultant CEO (who acquired his first 100 shares for $23.00 on June 17, 2016), the part-time consultant CFO (who owns zero shares); and
  • 3 other beneficial shareholders who all presently are now or have previously been directors and/or officers of the Company (Victor Redekop, a current director, Charles W. Baker, a former director and officer and Lyle Wunderlich, a former director).
• The 3 other shareholders collectively control or direct approximately 22,652,639 or 33.7% of the issued and outstanding shares and among them also hold options, warrants and other securities convertible into additional shares.

Again we ask the question, who are the true dissidents here? The true overwhelming number of shareholders of the struggling Company - or a tight little team with minimal confirmed supporters presiding over the continuing decline led by a consultant with a token $23 investment trying to hold on to his high paying consultancy fees?

Although support is clear for change, shareholders who have not yet voted their BLUE voting form are encouraged to have their voices heard and vote today as soon as possible by no later than 12:00 noon P.M. (Calgary Time).

Call for Action

We would encourage all shareholders to attend the meeting and stand up for change. The meeting will be held at 2:00 P.M. (Mountain Standard time) on Thursday, September 8, 2016 at the offices of Heighington Law Firm, 730, 1015 - 4^th Street S.W., Calgary, Alberta. We hope to see you there.

We once again thank shareholders for the significant support shown so far. Although support for the Concerned Shareholders is emphatic, given Management's actions to date, shareholders should be wary of any tactics they may use to try to invalidate your vote and disenfranchise you. Therefore, shareholders who have received their BLUE forms late and have not voted yet, we urge you to continue to vote. It is important that management fully appreciate and understand the level of discontent and the strong desire for change.

We once again thank shareholders for the significant support shown so far. Although support for the Concerned Shareholders is emphatic, given Management's actions to date, shareholders should be wary of any tactics they may use to try to invalidate your vote and disenfranchise you. Therefore, shareholders who have received their BLUE voting forms late and have not voted yet, we urge you to continue to vote. It is important that management fully appreciate and understand the level of discontent and the strong desire for change.

Time is of the essence. Vote online or by telephone by following the instructions found in the BLUE voting form mailed to you. Discard Management's voting form and only the BLUE voting form well in advance of the impending deadline of 12:00 noon P.M. (Calgary time) on September 6, 2016. If you have already voted using management's form but wish to support the Concerned Shareholders, simply recast your vote using the BLUE voting form. A later dated vote will supersede a previous vote.

Questions, Requests for assistance with voting may be directed to the Concerned Shareholders' Proxy Solicitor:

Laurel Hill Advisory Group

North America

Toll Free: 1-877-452-7184

Collect Calls Outside North America: 416-304-0211

Email: assistance@laurelhill.com

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this news release are forward-looking statements. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including, without limitation, risks and uncertainties related to actions taken by the Company or shareholders in connection with the Meeting. No assurance can be given that any of the events or outcomes anticipated by any forward-looking statement will occur.